Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1982 - Discovery of novel 1,3,5-triazine-thiozolidine (DDDL-251) based dual PI3K/mTOR inhibitor against breast cancer (8P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Udaya Singh

Citation

Annals of Oncology (2017) 28 (suppl_10): x1-x6. 10.1093/annonc/mdx652

Authors

U. Singh1, A. Verma2, H.R. Bhat3

Author affiliations

  • 1 Drug Design & Discovery Laboratory, Department Of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, 211007 - Allahabad/IN
  • 2 Department Of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, 211007 - Allahabad/IN
  • 3 Department Of Pharmaceutical Sciences, Dibrugarh University, 786004 - Dibrugarh/IN
More

Resources

Abstract 1982

Background

The targeting of phosphatidylinositol 3-kinase (PI3K) by selective inhibitors has emerged as a newer therapeutic option to reduce the burden of the cancer. The involvement of PI3K/mTOR in the progression of breast cancer is widely documented, and, as a result, numerous compounds are being assessed in clinical trials. In our previous study, we have discovered novel small molecules targeting breast cancer both in vitro and in vivo in micromolar concentration. Thus, in the present study, we intended to develop novel 1,3,5-triazine-thiozolidine based dual PI3K/mTOR inhibitor against breast cancer.

Methods

The compounds were synthesized in excellent yield and subsequently tested for anticancer activity against ER-positive (MCF-7) and ER-negative (MDA-MB-231) human breast cancer cell lines and MCF 12A (normal epithelial breast cell line) using MTT assay. The inhibitory activity against PI3K and mTOR were also estimated. The 3D-crystal structure of both PI3K and mTOR was used for the docking with DDD-251 to explore key structural contacts.

Results

The anticancer activity data revealed that compound DDDL-251 exhibits potent anticancer activity against MCF-7 and MDA-MB-231 cell lines, with the IC50 of 0.34 µM and 0.98 µM, respectively. The results of cell cycle analysis indicated that DDDL-251 causes G1/S cell cycle arrest. It was also shown to attenuate the PI3K and mTOR with IC50 of 4.05 µM and 6.55 µM, respectively. The docking analysis suggests that, DDDL-251 was able to fit into the ATP pocket of catalytic site of both PI3K amd mTOR with the Ki of 5.02 µM and 8.62 µM, respectively. Moreover, the compound was found non-toxic to the MCF 12A cells.

Conclusions

Based upon the potent anti-breast cancer activity, non-toxicity and selective targeting of both PI3K and mTOR, compound DDDL-251 could serve as a lead for future inhibitors.

Clinical trial identification

Legal entity responsible for the study

Sam Higginbottom University of Agriculture, technology and Sciences.

Funding

Sam Higginbottom University of Agriculture, Technology and Sciences.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings